文献速递心胸血管麻醉

体外循环后肝素逆转的鱼精蛋白剂量优化:群体药代动力学-药效学研究

Optimising protamine dosing for heparin reversal after cardiopulmonary bypass: a population pharmacokinetic-pharmacodynamic study.
PubMed 文献 · Br J Anaesth · 2026-02-04

该前瞻性单中心研究纳入68例体外循环心脏手术成人患者,采集757份血样构建群体药代动力学-药效模型,模拟不同鱼精蛋白与肝素比值下完全逆转的概率。模型预测鱼精蛋白与肝素比值0.625:1可使95%患者达到完全逆转,而ACT在低抗Xa活性时变异性大。

要点

  • 鱼精蛋白与肝素比值0.625:1可实现95%患者完全逆转。
  • ACT在低抗Xa活性时变异性大,可靠性有限。
  • 固定低比值给药无需常规监测,但需前瞻性验证。

核心结论

  • 鱼精蛋白与肝素比值0.625:1可提供充分的普通肝素逆转。
  • 鉴于ACT不精确,固定低比值给药无需常规监测或为实用替代方案,但需前瞻性验证。

研究设计与样本

  • 前瞻性单中心研究,纳入68例体外循环心脏手术成人患者。
  • 术中及肝素逆转后采集757份血样,测量抗Xa活性和ACT。
  • 采用非线性混合效应方法构建群体药代动力学-药效模型,并进行蒙特卡洛模拟。

主要发现

  • 鱼精蛋白启动后10分钟内所有患者抗Xa活性降至<0.10 IU ml-1。
  • 模型模拟预测鱼精蛋白与肝素比值0.625:1可使95%患者完全逆转。
  • ACT与抗Xa活性正相关,但低抗Xa浓度时ACT值变异性大。

关键数值与推荐

  • 完全逆转定义为抗Xa活性<0.10 IU ml-1。
  • 模型预测鱼精蛋白与肝素比值0.625:1可实现95%患者完全逆转。

临床怎么用

  • 体外循环后肝素逆转可考虑鱼精蛋白与肝素比值0.625:1。
  • 固定低比值给药无需常规监测ACT或抗Xa活性,但需前瞻性验证。

局限性

  • 单中心研究,样本量68例。
  • 固定低比值给药方案需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Protamine is administered to reverse unfractionated heparin (UFH) after cardiopulmonary bypass (CPB), but dosing strategies-typically based on protamine-to-heparin (P:H) ratios-vary, and the minimal effective dose remains unclear. Reversal is commonly assessed using activated clotting time (ACT), which may not reliably reflect residual heparin activity. We used pharmacometric modeling to determine a minimal effective P:H ratio and to characterise the anti-factor Xa (anti-Xa) activity-ACT relationship. METHODS: In this prospective, single-centre study, 68 adults undergoing CPB-assisted cardiac surgery were enrolled. A total of 757 blood samples were collected intraoperatively and after UFH reversal to measure anti-Xa activity and ACT. A population pharmacokinetic-pharmacodynamic model was developed using a nonlinear mixed-effects approach to describe UFH neutralisation by protamine. This model was then used to perform Monte Carlo simulations estimating the probability of complete reversal (anti-Xa <0.10 IU ml-1) at various P:H ratios, based on cumulative intraoperative UFH dose. RESULTS: Patients received a mean total dose of 30 250 IU UFH and 200 mg protamine i.v. Measured anti-Xa activity decreased to <0.10 IU ml-1 in all patients within 10 min of protamine initiation, indicating rapid reversal. Model-based simulations predicted that a P:H ratio of 0.625:1 would achieve complete reversal in 95% of patients. Although ACT and anti-Xa activity were positively associated, ACT values varied widely at low anti-Xa concentrations. CONCLUSIONS: A P:H ratio of 0.625:1 provided adequate UFH reversal. Given the imprecision of ACT, fixed low-ratio dosing without routine monitoring could be a practical alternative but requires prospective validation. CLINICAL TRIAL REGISTRATION: EudraCT (2019-000859-14); www. CLINICALTRIALS: gov (NCT04092868).

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Lanoiselée J, Gibert A, Gouin-Thibault I, et al. Optimising protamine dosing for heparin reversal after cardiopulmonary bypass: a population pharmacokinetic-pharmacodynamic study. Br J Anaesth. 2026. PMID: 41638976. doi:10.1016/j.bja.2025.11.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。